Cancer incidence is on the rise, particularly among younger adults, but most new drug compounds fail to progress through clinical trials.
Cancer Crisis
Orakl Oncology applies AI and combines data and biology to address the problem with clinical trial design.
Data-Driven Approach
Orakl operates at the intersection of data and biology, using avatars that combine patient background with tissue.
Hybrid Model
Orakl plans to commercialize two products: O-Predict for forecasting patient response and O-Validate for validating drug candidates.
Commercialization Plans